SequelSEC

ProPhase Labs, Inc. PRPH

Pharmaceutical Preparations · CIK 0000868278 · Fiscal year ends 1231

Revenue
$4.34M
Fiscal year ended 2025-12-31
Operating income
-$18.05M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ProPhase Labs, Inc. (PRPH) reported revenue of $4.34M and net income of -$14.74M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ProPhase Labs, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ProPhase Labs, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.34M$6.77M$34.98M$122.65M$79.04M$14.51M$9.88M$13.13M$9.87M$4.21M
Cost of revenue$2.96M$6.92M$19.43M$51.99M$37.05M$9.91M$7.26M$8.34M$7.92M$3.21M
Gross profit$1.38M-$150.00K$15.56M$70.65M$41.99M$4.61M$2.62M$4.78M$1.95M$997.00K
Operating income-$18.05M-$38.63M-$21.22M$23.60M$9.80M-$2.08M-$3.24M-$1.63M-$3.99M-$2.66M
Net income-$14.74M-$53.36M-$16.78M$18.46M$6.27M-$2.12M-$3.15M-$1.74M$40.59M-$2.87M
Research & development$107.00K$594.00K$1.40M$652.00K$520.00K$633.00K$332.00K$398.00K$431.00K$358.00K
Weighted-average diluted sharesshares 8.49Mshares 2.00Mshares 17.21Mshares 18.65Mshares 18.39Mshares 11.60MUnavailableshares 11.40Mshares 15.70Mshares 17.08M
Pretax income-$23.39M-$42.33M-$22.40M$22.91M$5.30M-$2.31M-$3.11M-$1.47M-$3.66M-$4.01M
Income tax expense$0$7.20M-$6.02M$4.44M-$968.00K$12.00KUnavailable$103.00K-$1.42MUnavailable
Diluted EPS$-1.74$-26.68$-0.98$1.02$0.40$-0.18Unavailable$-0.15$2.59$-0.17
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$5.52M$6.02M$5.51M$4.43M
General & administrative$19.32M$37.88M$33.44M$34.38M$22.49M$7.50M$4.48M$4.91M$4.81M$2.73M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable$1.29M$1.04M$1.11M$699.00K$1.70M

Balance

ProPhase Labs, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$90.00K$678.00K$1.61M$9.11M$8.41M$6.82M$434.00K$1.55M$3.17M$441.00K
Total assets$59.87M$63.20M$91.93M$87.65M$89.30M$31.40M$12.27M$20.74M$33.66M$12.80M
Current assets$3.15M$30.64M$47.58M$60.83M$61.32M$15.89M$9.94M$18.24M$28.42M$9.63M
Total liabilities$56.36M$55.85M$42.54M$24.02M$30.67M$20.85M$1.04M$4.23MUnavailableUnavailable
Current liabilities$53.08M$32.13M$20.86M$16.08M$15.52M$6.29M$933.00K$4.23M$1.81M$6.84M
Total equity incl. NCI$3.51M$7.35M$49.38M$63.63M$58.63M$10.56M$11.23M$16.50M$31.85M$5.96M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$70.00K$1.14M$2.29M$3.98M$4.60M$3.04M$1.46M$1.90M$1.53M$2.74M
Accounts receivable$1.54M$20.06M$35.81M$37.05M$37.71M$3.16M$2.01M$2.97M$1.94M$5.77M
Goodwill$3.97M$5.23M$5.23M$5.71M$5.71M$901.00KUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$2.92M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailable$13.72M$8.64M$5.90M$7.03M$3.77M$432.00K$437.00K$562.00K$2.16M

Cash flow

ProPhase Labs, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$8.34M-$17.54M-$11.89M$28.55M-$13.62M-$2.59M-$841.00K-$2.12M-$2.84M-$472.00K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$140.00K$208.00K$651.00K
Investing cash flow$920.00K$2.42M-$1.37M-$2.08M-$19.67M-$1.02M$5.54M$11.86M$21.77M-$651.00K
Financing cash flow$6.84M$14.18M$5.76M-$26.02M$35.13M$9.99M-$5.82M-$11.36M-$16.20M-$100.00K
Net change in cash-$588.00K-$931.00K-$7.50M$451.00K$1.84M$6.38M-$1.12M-$1.62M$2.73M-$1.22M
Stock-based compensation$1.89M$3.64M$3.54M$3.99M$3.18M$1.46M$744.00K$634.00K$78.00K$1.00K
Common dividends paidUnavailableUnavailable$0$9.35M$4.55MUnavailable$5.82M$11.70MUnavailableUnavailable
Common share repurchasesUnavailable$0$588.00K$2.15M$917.00KUnavailableUnavailableUnavailable$16.28MUnavailable
Depreciation & amortization$4.83M$6.19M$6.05M$4.72M$3.23M$449.00K$398.00K$383.00K$337.00K$426.00K

Derived

ProPhase Labs, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$3.05M-$1.12M
Gross margin31.9%-2.2%44.5%57.6%53.1%31.7%26.5%36.4%19.7%23.7%
Operating margin-415.4%-570.6%-60.7%19.2%12.4%-14.3%-32.8%-12.4%-40.4%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-30.9%-26.7%
SBC / revenue43.6%53.7%10.1%3.2%4.0%10.1%7.5%4.8%0.8%0.0%
Current ratio0.06x0.95x2.28x3.78x3.95x2.52x10.66x4.31x15.68x1.41x
Revenue YoY growth-35.8%-80.6%-71.5%55.2%444.6%47.0%-24.8%33.0%134.6%Unavailable
Net margin-339.3%-788.2%-48.0%15.1%7.9%-14.6%-31.9%-13.3%411.4%-68.2%
R&D / revenue2.5%8.8%4.0%0.5%0.7%4.4%3.4%3.0%4.4%8.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable2.1%15.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable19.4%-18.2%UnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PRPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q/A · Filed 2026-07-09View SEC filing
10-Q/A · Filed 2026-07-07View SEC filing
10-Q · Filed 2026-06-30View SEC filing
10-K · Filed 2026-06-01View SEC filing
10-Q · Filed 2025-11-19View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.